Targeting nerve growth factor in pain: What is the therapeutic potential?

BioDrugs

Volumn 22, Issue 6, 2008, Pages 349-359

  Watson, Judy J ^a   Allen, Shelley J ^a   Dawbarn, David ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Nerve growth factor modulators, therapeutic use; Nerve growth factors, general; Pain, treatment; Research and development

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLOMIPRAMINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; FENTANYL; GABAPENTIN; HYDROCORTISONE; LIDOCAINE; MNAC13; MONOCLONAL ANTIBODY; MORPHINE; N (2 HYDROXYETHYLAMINO) 3 NITRONAPHTHALIMIDE; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PD 90780; PHENYTOIN; PREDNISONE; PREGABALIN; PROTEIN TRKAD5; PROTEIN TYROSINE KINASE A; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

BONE PAIN; CANCER PAIN; CHRONIC PAIN; COGNITIVE DEFECT; CONSTIPATION; CYSTITIS; DROWSINESS; DRUG DEPENDENCE; DRUG MECHANISM; ERYTHEMA; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERALGESIA; IMMUNE DEFICIENCY; INSOMNIA; KIDNEY INJURY; LETHARGY; LIVER INJURY; MOOD CHANGE; NAUSEA; NEUROPATHIC PAIN; NOCICEPTION; OSTEOARTHRITIS; PAIN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RASH; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SKIN MANIFESTATION; ULTRAVIOLET IRRADIATION; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

ANALGESICS; ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; NERVE GROWTH FACTOR; PAIN; PEPTIDES; RECEPTOR, TRKA; SIGNAL TRANSDUCTION;

EID: 56149111648     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/0063030-200822060-00002     Document Type: Review

References (114)

1. Fricker J. Pain in Europe: a report [online]. Available from URL: http://www.paineurope.com/index.php?q=en/book_page/the_pain_in_europe_report [Accessed 2008 Jul 23]
2. Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006; 29: 507-38
3. Pingle SC, Matta JA, Ahern GP. Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol 2007; (179): 155-71
4. Lacroix-Fralish ML, Ledoux JB, Mogil JS. The pain genes database: an interactive web browser of pain-related transgenic knockout studies. Pain 2007; 131: 3-4
5. Souslova V, Cesare P, Ding Y, et al. Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature 2000; 407: 1015-7
6. Sluka KA, Price MP, Breese NM, et al. Chronic hyperalgesia induced by repeated acid injections in muscle is abolished by the loss of ASIC3, but not ASIC1. Pain 2003; 106: 229-39
7. Rupniak NM, Boyce S, Webb JK, et al. Effects of the bradykinin B1 receptor antagonist des-Arg9[Leu8]bradykinin and genetic disruption of the B2 receptor on nociception in rats and mice. Pain 1997; 71: 89-97
8. Pesquero JB, Araujo RC, Heppenstall PA, et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A 2000; 97: 8140-5
9. Bolcskei K, Helyes Z, Szabo A, et al. Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice. Pain 2005; 117: 368-76
10. Akopian AN, Souslova V, England S, et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 1999; 2: 541-8
11. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008; 22: 383-90
12. Ottani A, Leone S, Sandrini M, et al. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol 2006; 531: 280-1
13. Zeilhofer HU. Prostanoids in nociception and pain. Biochem Pharmacol 2007; 73: 165-74
14. Flower RJ, Blackwell GJ. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979; 278: 456-9
15. Atici S, Cinel I, Cinel L, et al. Liver and kidney toxicity in chronic use of opioids: an experimental long term treatment model. J Biosci 2005; 30: 245-52
16. Thomas JR, von Gunten CF. Pain in terminally ill patients: guidelines for pharmacological management. CNS Drugs 2003; 17: 621-31
17. Schrijvers D. Pain control in cancer: recent findings and trends. Ann Oncol 2007; 18 Suppl. 9: ix37-42
18. McCleane G. Pharmacological management of neuropathic pain. CNS Drugs 2003; 17: 1031-43
19. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996; 65: 39-44
20. Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004; 112: 372-80
21. Levi-Montalcini R, Cohen S. In vitro and in vivo effects of a nerve growth-stimulating agent isolated from snake venom. Proc Natl Acad Sci U S A 1956; 42: 695-9
22. Barde YA, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J 1982; 1: 549-53
23. Ernfors P, Ibanez CF, Ebendal T, et al. Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographical expression in the brain. Proc Natl Acad Sci U S A 1990; 87: 5454-8
24. Berkemeier LR, Winslow JW, Kaplan DR, et al. Neurotrophin-5: a novel neurotrophic factor that activates trk and trkB. Neuron 1991; 7: 857-66
25. Allen SJ, Dawbarn D. Clinical relevance of the neurotrophins and their receptors. Clin Sci (Lond) 2006; 110: 175-91
26. Dawbarn D, Allen SJ. Neurotrophins and neurodegeneration. Neuropathol Appl Neurobiol 2003; 29: 211-30
27. Rodriguez-Tebar A, Dechant G, Barde YA. Binding of brain-derived neurotrophic factor to the nerve growth factor receptor. Neuron 1990; 4: 487-92
28. Martin-Zanca D, Oskam R, Mitra G, et al. Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol 1989; 9: 24-33
29. Klein R, Parada LF, Coulier F, et al. TrkB, a novel tyrosine protein kinase receptor expressed during mouse neural development. EMBO J 1989; 8: 3701-9
30. Lamballe F, Klein R, Barbacid M. TrkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 1991; 66: 967-79
31. He XL, Garcia KC. Structure of nerve growth factor complexed with the shared neurotrophin receptor p75. Science 2004; 304: 870-5
32. Aurikko JP, Ruotolo BT, Grossmann JG, et al. Characterization of symmetric complexes of nerve growth factor and the ectodomain of the pan-neurotrophin receptor, p75NTR. J Biol Chem 2005; 280: 33453-60
33. Schneider R, Schweiger M. A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors. Oncogene 1991; 6: 1807-11
34. Perez P, Coll PM, Hempstead BL, et al. NGF binding to the trk tyrosine kinase receptor requires the extracellular immunoglobulin-like domains. Mol Cell Neurosci 1995; 6: 97-105
35. Wiesmann C, Ultsch MH, Bass SH, et al. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature 1999; 401: 184-8
36. Ultsch MH, Wiesmann C, Simmons LC, et al. Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and TrkC. J Mol Biol 1999; 290: 149-59
37. Robertson AG, Banfield MJ, Allen SJ, et al. Identification and structure of the nerve growth factor binding site on TrkA. Biochem Biophys Res Commun 2001; 282: 131-41
38. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 2000; 10: 381-91
39. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003; 72: 609-42
40. Crowley C, Spencer SD, Nishimura MC, et al. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 1994; 76: 1001-11
41. Smeyne RJ, Klein R, Schnapp A, et al. Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature 1994; 368: 246-9
42. Davis BM, Lewin GR, Mendell LM, et al. Altered expression of nerve growth factor in the skin of transgenic mice leads to changes in response to mechanical stimuli. Neuroscience 1993; 56: 789-92
43. Stucky CL, Koltzenburg M, Schneider M, et al. Overexpression of nerve growth factor in skin selectively affects the survival and functional properties of nociceptors. J Neurosci 1999; 19: 8509-16
44. Indo Y, Tsuruta M, Hayashida Y, et al. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet 1996; 13: 485-8
45. Mardy S, Miura Y, Endo F, et al. Congenital insensitivity to pain with anhidrosis: novel mutations in the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve growth factor. Am J Hum Genet 1999; 64: 1570-9
46. Huehne K, Zweier C, Raab K, et al. Novel missense, insertion and deletion mutations in the neurotrophic tyrosine kinase receptor type 1 gene (NTRK1) associated with congenital insensitivity to pain with anhidrosis. Neuromuscul Disord 2008 Feb; 18 (2): 159-66
47. Einarsdottir E, Carlsson A, Minde J, et al. A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception. Hum Mol Genet 2004; 13: 799-805
48. Lowe EM, Anand P, Terenghi G, et al. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol 1997; 79: 572-7
49. Aloe L, Tuveri MA, Carcassi U, et al. Nerve growth factor in the synovial fluid of patients with chronic arthritis. Arthritis Rheum 1992; 35: 351-5
50. Halliday DA, Zettler C, Rush RA, et al. Elevated nerve growth factor levels in the synovial fluid of patients with inflammatory joint disease. Neurochem Res 1998; 23: 919-22
51. Friess H, Zhu ZW, di Mola FF, et al. Nerve growth factor and its high-affinity receptor in chronic pancreatitis. Ann Surg 1999; 230: 615-24
52. Lewin GR, Ritter AM, Mendell LM. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. J Neurosci 1993; 13: 2136-48
53. Andreev NY, Dimitrieva N, Koltzenburg M, et al. Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neurones. Pain 1995; 63: 109-15
54. Petty BG, Cornblath DR, Adornato BT, et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994; 36: 244-6
55. Dyck PJ, Peroutka S, Rask C, et al. Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans. Neurology 1997; 48: 501-5
56. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002; 50: 393-413
57. Svensson P, Cairns BE, Wang K, et al. Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. Pain 2003; 104: 241-7
58. Leon A, Buriani A, Dal Toso R, et al. Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci U S A 1994; 91: 3739-43
59. Bergmann I, Reiter R, Toyka KV, et al. Nerve growth factor evokes hyperalgesia in mice lacking the low-affinity neurotrophin receptor p75. Neurosci Lett 1998; 255: 87-90
60. Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006; 27: 85-91
61. Averill S, McMahon SB, Clary DO, et al. Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons. Eur J Neurosci 1995; 7: 1484-94
62. Priestley JV, Michael GJ, Averill S, et al. Regulation of nociceptive neurons by nerve growth factor and glial cell line derived neurotrophic factor. Can J Physiol Pharmacol 2002; 80: 495-505
63. Delcroix JD, Valletta JS, Wu C, et al. NGF signaling in sensory neurons: evidence that early endosomes carry NGF retrograde signals. Neuron 2003; 39: 69-84
64. Shu X, Mendell LM. Nerve growth factor acutely sensitizes the response of adult rat sensory neurons to capsaicin. Neurosci Lett 1999; 274: 159-62
65. Zhu W, Oxford GS. Phosphoinositide-3-kinase and mitogen activated protein kinase signaling pathways mediate acute NGF sensitization of TRPV1. Mol Cell Neurosci 2007; 34: 689-700
66. Chuang HH, Prescott ED, Kong H, et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001; 411: 957-62
67. Bonnington JK, McNaughton PA. Signalling pathways involved in the sensitisation of mouse nociceptive neurones by nerve growth factor. J Physiol 2003; 551: 433-46
68. Cesare P, Dekker LV, Sardini A, et al. Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat. Neuron 1999; 23: 617-24
69. Premkumar LS, Ahern GP. Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000; 408: 985-90
70. Numazaki M, Tominaga T, Toyooka H, et al. Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cepsilon and identification of two target serine residues. J Biol Chem 2002; 277: 13375-8
71. Zhuang ZY, Xu H, Clapham DE, et al. Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J Neurosci 2004; 24: 8300-9
72. Ji RR, Samad TA, Jin SX, et al. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002; 36: 57-68
73. Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J 2005; 24: 4211-23
74. Stein AT, Ufret-Vincenty CA, Hua L, et al. Phosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membrane. J Gen Physiol 2006; 128: 509-22
75. Winston J, Toma H, Shenoy M, et al. Nerve growth factor regulates VR-1 mRNA levels in cultures of adult dorsal root ganglion neurons. Pain 2001; 89: 181-6
76. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008; 7: 21-39
77. Porter CJ, Edwards GA, Charman SA. Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv Drug Deliv Rev 2001; 50: 157-71
78. Kompella UB, Lee VH. Pharmacokinetics of peptide and protein drugs. In: Lee V HL, editor. Peptide and protein drug delivery. New York: Marcel Dekker, 1991: 391-484
79. Toon S. The relevance of pharmacokinetics in the development of biotechnology products. Eur J Drug Metab Pharmacokinet 1996; 21: 93-103
80. McMahon SB, Bennett DL, Priestley JV, et al. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med 1995; 1: 774-80
81. Koltzenburg M, Bennett DL, Shelton DL, et al. Neutralization of endogenous NGF prevents the sensitization of nociceptors supplying inflamed skin. Eur J Neurosci 1999; 11: 1698-704
82. Ro LS, Chen ST, Tang LM, et al. Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction injury of the sciatic nerve. Pain 1999; 79: 265-74
83. Gwak YS, Nam TS, Paik KS, et al. Attenuation of mechanical hyperalgesia following spinal cord injury by administration of antibodies to nerve growth factor in the rat. Neurosci Lett 2003; 336: 117-20
84. Halvorson KG, Kubota K, Sevcik MA, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005; 65: 9426-35
85. Koewler NJ, Freeman KT, Buus RJ, et al. Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur. J Bone Miner Res 2007; 22: 1732-42
86. Jimenez-Andrade JM, Martin CD, Koewler NJ, et al. Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. Pain 2007; 133: 183-96
87. Hongo JS, Laramee GR, Urfer R, et al. Antibody binding regions on human nerve growth factor identified by homolog- and alanine-scanning mutagenesis. Hybridoma 2000; 19: 215-27
88. Wild KD, Bian D, Zhu D, et al. Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance. J Pharmacol Exp Ther 2007; 322: 282-7
89. Amgen®. AMG 403 [online]. Available from URL: http://www.amgen.com/ science/pipe_AMG403.html [Accessed 2008 12 Aug]
90. Ruberti F, Bradbury A, Cattaneo A. Cloning and expression of an anti-nerve growth factor (NGF) antibody for studies using the neuroantibody approach. Cell Mol Neurobiol 1993; 13: 559-68
91. Capsoni S, Ugolini G, Comparini A, et al. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci U S A 2000; 97: 6826-31
92. Marinelli S, Ugolini G, Cattaneo A, et al. Analgesic effects of anti-NGF and anti-TrkA antibodies on neuropathic pain in mice and rapid functional recovery. Expanding Vistas in Neuropathic Pain; 2005 Aug 17-20; Uluru
93. Ugolini G, Marinelli S, Covaceuszach S, et al. Effects of anti-NGF and anti-TrkA antibodies on inflammatory pain in mice. FENS Forum Abstracts 2004; 2: A121.22
94. Holden PH, Asopa V, Robertson AG, et al. Immunoglobulin-like domains define the nerve growth factor binding site of the TrkA receptor. Nat Biotechnol 1997; 15: 668-72
95. Banfield MJ, Naylor RL, Robertson AG, et al. Specificity in Trk receptor:neurotrophin interactions: the crystal structure of TrkB-d5 in complex with neurotrophin-4/5. Structure 2001; 9: 1191-9
96. Wehrman T, He X, Raab B, et al. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron 2007; 53: 25-38
97. Watson JJ, Fahey MS, van den WE, et al. TrkAd5: a novel therapeutic agent for treatment of inflammatory pain and asthma. J Pharmacol Exp Ther 2006; 316: 1122-9
98. Djouhri L, Dawbarn D, Robertson A, et al. Time course and nerve growth factor dependence of inflammation-induced alterations in electrophysiological membrane properties in nociceptive primary afferent neurons. J Neurosci 2001; 21: 8722-33
99. Pasricha J, Winston J, Wang W, et al. NGF induces sensitisation of the vanilloid receptor (TRPV1) response in sensory neurons in acute pancreatitits by recruiting silent nociceptors. Gastroenterology 2005; 128 Suppl. 2: 588
100. Hu VY, Zvara P, Dattilio A, et al. Decrease in bladder overactivity with REN1820 in rats with cyclophosphamide induced cystitis. J Urol 2005; 173: 1016-21
101. Bishop T, Hewson DW, Yip PK, et al. Characterisation of ultraviolet-B-induced inflammation as a model of hyperalgesia in the rat. Pain 2007; 131: 70-82
102. Sutherland S. Peptibodies: the new cool technology. Drug Discov Today 2004; 9: 683
103. Ugolini G, Marinelli S, Covaceuszach S, et al. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc Natl Acad Sci U S A 2007; 104: 2985-90
104. Cattaneo A, Capsoni S, Margotti E, et al. Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody. J Neurosci 1999; 19: 9687-97
105. Covaceuszach S, Cattaneo A, Lamba D. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight. Proteins 2005; 58: 717-27
106. LeSauteur L, Wei L, Gibbs BF, et al. Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses. J Biol Chem 1995; 270: 6564-9
107. Owolabi JB, Rizkalla G, Tehim A, et al. Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. J Pharmacol Exp Ther 1999; 289: 1271-6
108. Colquhoun A, Lawrance GM, Shamovsky IL, et al. Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzolylamino)-4,9-dihydro- 4-methyl-9-oxo-pyrazolo[5,1-b]quinazoline-2-carboxylic acid] suggests altered NGF-p75NTR interactions in the presence of TrkA. J Pharmacol Exp Ther 2004; 310: 505-11
109. PainCeptor. NGF: background [online]. Available from URL: http://www.painceptor.com/page.asp?IntNodeID=15183 [Accessed 2008 12 Aug]
110. Dawbarn D, Fahey M, Watson J, et al. NGF receptor TrkAd5: therapeutic agent and drug design target. Biochem Soc Trans 2006; 34: 587-90
111. Winston JH, Toma H, Shenoy M, et al. Acute pancreatitis results in referred mechanical hypersensitivity and neuropeptide up-regulation that can be suppressed by the protein kinase inhibitor k252a. J Pain 2003; 4: 329-37
112. Lippa B, Morris J, Corbett M, et al. Discovery of novel isothiazole inhibitors of the TrkA kinase: structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists. Bioorg Med Chem Lett 2006; 16: 3444-8
113. Zhang HS, Krisky D, McNamara AR, et al. An engineered zinc finger protein transcriptional repressor of TrkA reduces nociception in a mouse model of bone cancer pain [poster no. 182.4/NN20]. Neuroscience 2007; 2007 Nov 3-7; San Diego (CA)
114. Sangamo BioSciences Inc. Human therapeutics overview [online]. Available from URL: http://www.sangamo.com/human/human_thera_overview.html#intract [Accessed 2008 Aug 12]